Ibio Inc is a biotechnology company that focuses on the development and commercialization of innovative biologic therapies for various diseases
Utilizing its proprietary plant-based expression platform, the company aims to create a range of scalable, cost-effective solutions for producing proteins and antibodies that can be used in therapies and vaccines. Ibio also engages in collaborations and partnerships to accelerate the development of its product pipeline and enhance its technology, ultimately striving to improve patient outcomes in areas such as infectious diseases and cancer.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
iBio advances obesity treatment with IBIO-600, a long-acting anti-myostatin antibody designed for subcutaneous use, targeting reduced dosing frequency.
iBio surged after collaborating with AstralBio Inc. to develop antibodies for obesity & cardiometabolic conditions. Shares soared over 100%, hitting $2.44. Collaboration aims to target TGFb superfamily for muscle wasting & obesity treatment.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500 also fell, dropping, 0.07% to 4,566.73.
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P 500 also fell, dropping, 0.03% to 4,568.46.
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell 0.40% to 14,129.09. The S&P 500 also fell, dropping, 0.30% to 4,556.06.
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a stro
